Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 29 of 29 entries
Sorted by: Best Match Show Resources per page
Serum zonulin levels in patients with liver cirrhosis: Prognostic implications.

World journal of hepatology

Voulgaris TA, Karagiannakis D, Hadziyannis E, Manolakopoulos S, Karamanolis GP, Papatheodoridis G, Vlachogiannakos J.
PMID: 34786174
World J Hepatol. 2021 Oct 27;13(10):1394-1404. doi: 10.4254/wjh.v13.i10.1394.

BACKGROUND: Increased gut permeability and bacterial translocation play an important role in liver cirrhosis. Zonulin is a recently recognized protein involved in the disintegration of the intestinal barrier.AIM: To investigate possible differences in serum zonulin levels among patients with...

Cite
Voulgaris TA, Karagiannakis D, Hadziyannis E, et al. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. World J Hepatol. 2021;13(10):1394-1404doi: 10.4254/wjh.v13.i10.1394.
Voulgaris, T. A., Karagiannakis, D., Hadziyannis, E., Manolakopoulos, S., Karamanolis, G. P., Papatheodoridis, G., & Vlachogiannakos, J. (2021). Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. World journal of hepatology, 13(10), 1394-1404. https://doi.org/10.4254/wjh.v13.i10.1394
Voulgaris, Theodoros A, et al. "Serum zonulin levels in patients with liver cirrhosis: Prognostic implications." World journal of hepatology vol. 13,10 (2021): 1394-1404. doi: https://doi.org/10.4254/wjh.v13.i10.1394
Voulgaris TA, Karagiannakis D, Hadziyannis E, Manolakopoulos S, Karamanolis GP, Papatheodoridis G, Vlachogiannakos J. Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. World J Hepatol. 2021 Oct 27;13(10):1394-1404. doi: 10.4254/wjh.v13.i10.1394. PMID: 34786174; PMCID: PMC8568570.
Copy Download .nbib Format: NLM
Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".

Hepatology international

Hadziyannis SJ.
PMID: 19669350
Hepatol Int. 2007 Jun;1(2):281-4. doi: 10.1007/s12072-007-9004-7.

No abstract available.

Cite
Hadziyannis SJ. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatol Int. 2007;1(2):281-4doi: 10.1007/s12072-007-9004-7.
Hadziyannis, S. J. (2007). Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatology international, 1(2), 281-4. https://doi.org/10.1007/s12072-007-9004-7
Hadziyannis, Stephanos J. "Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state"." Hepatology international vol. 1,2 (2007): 281-4. doi: https://doi.org/10.1007/s12072-007-9004-7
Hadziyannis SJ. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hepatol Int. 2007 Jun;1(2):281-4. doi: 10.1007/s12072-007-9004-7. PMID: 19669350; PMCID: PMC2716827.
Copy Download .nbib Format: NLM
Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D.

Annals of gastroenterology

Konstantinides P, Alexopoulou A, Hadziyannis E, Kanellopoulou T, Dourakis SP.
PMID: 30386121
Ann Gastroenterol. 2018 Nov-Dec;31(6):705-711. doi: 10.20524/aog.2018.0310. Epub 2018 Sep 14.

BACKGROUND: Several studies have provided conflicting results regarding the immune responses in chronic hepatitis C (CHC) patients with mixed cryoglobulinemia (MC). The importance of B-cell activating factor (BAFF) in MC has been described, but the role of interleukin (IL)-17A...

Cite
Konstantinides P, Alexopoulou A, Hadziyannis E, et al. Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D. Ann Gastroenterol. 2018;31(6):705-711doi: 10.20524/aog.2018.0310.
Konstantinides, P., Alexopoulou, A., Hadziyannis, E., Kanellopoulou, T., & Dourakis, S. P. (2018). Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D. Annals of gastroenterology, 31(6), 705-711. https://doi.org/10.20524/aog.2018.0310
Konstantinides, Polydoros, et al. "Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D." Annals of gastroenterology vol. 31,6 (2018): 705-711. doi: https://doi.org/10.20524/aog.2018.0310
Konstantinides P, Alexopoulou A, Hadziyannis E, Kanellopoulou T, Dourakis SP. Interleukin-17A and B-cell activating factor in chronic hepatitis C patients with or without asymptomatic mixed cryoglobulinemia: effects of antiviral treatment and correlations with vitamin D. Ann Gastroenterol. 2018 Nov-Dec;31(6):705-711. doi: 10.20524/aog.2018.0310. Epub 2018 Sep 14. PMID: 30386121; PMCID: PMC6191865.
Copy Download .nbib Format: NLM
Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients.

Frontiers in immunology

Makris A, Adamidi S, Koutsianas C, Tsalapaki C, Hadziyannis E, Vassilopoulos D.
PMID: 29375580
Front Immunol. 2018 Jan 10;8:1967. doi: 10.3389/fimmu.2017.01967. eCollection 2017.

OBJECTIVES: Granulocyte monocyte colony-stimulating factor (GM-CSF) is currently considered a crucial inflammatory mediator and a novel therapeutic target in rheumatoid arthritis (RA), despite the fact that its precise cellular sources remain uncertain. We studied the expression of GM-CSF in...

Cite
Makris A, Adamidi S, Koutsianas C, et al. Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients. Front Immunol. 2018;8:1967doi: 10.3389/fimmu.2017.01967.
Makris, A., Adamidi, S., Koutsianas, C., Tsalapaki, C., Hadziyannis, E., & Vassilopoulos, D. (2017). Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients. Frontiers in immunology, 81967. https://doi.org/10.3389/fimmu.2017.01967
Makris, Anastasia, et al. "Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients." Frontiers in immunology vol. 8 (2017): 1967. doi: https://doi.org/10.3389/fimmu.2017.01967
Makris A, Adamidi S, Koutsianas C, Tsalapaki C, Hadziyannis E, Vassilopoulos D. Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients. Front Immunol. 2018 Jan 10;8:1967. doi: 10.3389/fimmu.2017.01967. eCollection 2017. PMID: 29375580; PMCID: PMC5767588.
Copy Download .nbib Format: NLM
ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study.

Liver international : official journal of the International Association for the Study of the Liver

Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis G.
PMID: 34890120
Liver Int. 2021 Dec 10; doi: 10.1111/liv.15128. Epub 2021 Dec 10.

BACKGROUND & AIMS: Scarce data exist on the effect of nucleos(t)ide analogue (NA) discontinuation on hepatocellular carcinoma (HCC) risk in HBeAg-negative chronic hepatitis B (CHBe-). Therefore, we assessed whether HCC risk is increased in non-cirrhotic CHBe- patients who discontinue...

Cite
Papatheodoridi M, Su TH, Hadziyannis E, et al. ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. Liver Int. 2021;doi: 10.1111/liv.15128.
Papatheodoridi, M., Su, T. H., Hadziyannis, E., Liao, C. H., Orfanidou, �. �., Yang, H. C., Zachou, K., Liu, C. J., Kourikou, A., Gatselis, N., Manolakopoulos, S., Dalekos, G., Kao, J. H., Hadziyannis, S., & Papatheodoridis, G. (2021). ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. Liver international : official journal of the International Association for the Study of the Liver, . https://doi.org/10.1111/liv.15128
Papatheodoridi, Margarita, et al. "ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study." Liver international : official journal of the International Association for the Study of the Liver vol. (2021). doi: https://doi.org/10.1111/liv.15128
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis G. ssHepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicenter cohort study. Liver Int. 2021 Dec 10; doi: 10.1111/liv.15128. Epub 2021 Dec 10. PMID: 34890120.
Copy Download .nbib Format: NLM
Showing 25 to 29 of 29 entries